Other Metabolic Disorders - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 39 pages report, published by Global Markets Direct

Keywords : Other Metabolic Disorders Therapeutic Products under Development, Key Players in Other Metabolic Disorders Therapeutics, Other Metabolic Disorders Pipeline Overview, Other Metabolic Disorders Pipeline, Other Metabolic Disorders Pipeline Assessment

Report ThumbnailSeptember-2013
Other Metabolic Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Other Metabolic Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Metabolic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Metabolic Disorders. Other Metabolic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Metabolic Disorders.
- A review of the Other Metabolic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Metabolic Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Metabolic Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Metabolic Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Other Metabolic Disorders, H2 2013 7
  • Products under Development for Other Metabolic Disorders - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Mid Clinical Stage Products, H2 2013 10
  • Early Clinical Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 16
  • Assessment by Route of Administration, H2 2013 17
  • Assessment by Stage and Route of Administration, H2 2013 18
  • Assessment by Molecule Type, H2 2013 19
  • Assessment by Stage and Molecule Type, H2 2013 20
  • List of Tables
  • Number of Products Under Development for Other Metabolic Disorders, H2 2013 7
  • Products under Development for Other Metabolic Disorders - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Obio Pharmaceutical Holdings Limited., H2 2013 14
  • The Alize Pharma Group, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 16
  • Assessment by Stage and Route of Administration, H2 2013 18
  • Assessment by Stage and Molecule Type, H2 2013 20
  • Other Metabolic Disorders Therapeutics - Drug Profile Updates 28
  • Other Metabolic Disorders Therapeutics - Discontinued Products 30
  • Other Metabolic Disorders Therapeutics - Dormant Products 31
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Other Metabolic Disorders Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Other Metabolic Disorders 7
  • Other Metabolic Disorders Therapeutics under Development by Companies 9
  • Mid Clinical Stage Products 10
  • Comparative Analysis 10
  • Early Clinical Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Other Metabolic Disorders Therapeutics - Products under Development by Companies 13
  • Companies Involved in Other Metabolic Disorders Therapeutics Development 14
  • Obio Pharmaceutical Holdings Limited. 14
  • The Alize Pharma Group 15
  • Other Metabolic Disorders - Therapeutics Assessment 16
  • Assessment by Monotherapy Products 16
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 19
  • Drug Profiles 21
  • KP-624 - Drug Profile 21
  • Product Description 21
  • Mechanism of Action 21
  • R&D Progress 21
  • AZP-01 - Drug Profile 22
  • Product Description 22
  • Mechanism of Action 22
  • R&D Progress 22
  • UX-007 - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • XAF-5 - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • CAS-001 - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • CAS-003 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • CAS-045 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Other Metabolic Disorders Therapeutics - Drug Profile Updates 28
  • Other Metabolic Disorders Therapeutics - Discontinued Products 30
  • Other Metabolic Disorders Therapeutics - Dormant Products 31
  • Other Metabolic Disorders - Product Development Milestones 32
  • Featured News & Press Releases 32
  • Aug 28, 2013: Ultragenyx Announces Presentation of two Abstract at the 12th International Congress of Inborn Errors of Metabolism (ICIEM 2013) 32
  • Aug 26, 2013: Ultragenyx Investigational New Drug Application for UX007 is Active 32
  • Aug 05, 2013: Ultragenyx Initiates New Development Program Studying Triheptanoin (UX007) for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) 33
  • Jan 11, 2012: Bridge BioResearch Announces Completion Of Preclinical Trials Of 2hydroxyoleic Acid 34
  • Nov 01, 2011: KYTHERA Announces Preliminary Two-Year Follow-Up Study Results And Poster Presentation Of Phase IIb Data From Fat Reduction Drug At ASDS 34
  • Apr 14, 2011: CHMP Announces Positive Opinion For Carbaglu In Hyperammonaemia 34
  • Feb 15, 2011: Raptor To Enroll Five Additional Patients In Phase III Clinical Trial Of DR Cysteamine For Treatment Of Nephropathic Cystinosis 35
  • Feb 04, 2011: Kythera Reports Positive Results From Phase IIB Study With ATX-101 36
  • Oct 06, 2010: Arena And Eisai Report Lorcaserin Presentations At Obesity 2010 36
  • Oct 04, 2010: Orexigen Announces Upcoming Data Presentations At 28th Annual Scientific Meeting Of Obesity Society 37
  • Appendix 38
  • Methodology 38
  • Coverage 38
  • Secondary Research 38
  • Primary Research 38
  • Expert Panel Validation 38
  • Contact Us 39
  • Disclaimer 39

Please select a license type

Share

Related Products

Global Markets DirectOther Metabolic Disorders - Pipeline Review, H2 2013Product ThumbnailOther Metabolic Disorders - Pipeline Review, H2 2013, Industry ReportProduct #: 113315
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved